{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:13:07Z","timestamp":1761559987269},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1007\/s10384-009-0754-8","type":"journal-article","created":{"date-parts":[[2010,2,11]],"date-time":"2010-02-11T10:12:46Z","timestamp":1265883166000},"page":"7-14","source":"Crossref","is-referenced-by-count":26,"title":["Effects of switching to SofZia-preserved travoprost in patients who presented with superficial punctate keratopathy while under treatment with latanoprost"],"prefix":"10.1007","volume":"54","author":[{"given":"Sei","family":"Yamazaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mami","family":"Nanno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tairo","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Suzumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,2,12]]},"reference":[{"key":"754_CR1","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/j.1755-3768.2008.01250.x","volume":"86","author":"C. Baudouin","year":"2008","unstructured":"Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol 2008;86:716\u2013726.","journal-title":"Acta Ophthalmol"},{"key":"754_CR2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF02853166","volume":"18","author":"R. Noecker","year":"2001","unstructured":"Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther 2001;18:205\u2013215.","journal-title":"Adv Ther"},{"key":"754_CR3","first-page":"2047","volume":"60","author":"Y. Kitazawa","year":"2006","unstructured":"Kitazawa Y, Latanoprost Study Group. An open-label multicenter study on the efficacy and safety of topical use of latanoprost for 156 weeks. Rinsho Ganka (Jpn J Clin Ophthalmol) 2006;60:2047\u20132054.","journal-title":"Rinsho Ganka (Jpn J Clin Ophthalmol)"},{"key":"754_CR4","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1089\/jop.2007.0024","volume":"23","author":"B. McCarey","year":"2007","unstructured":"McCarey B, Edelhauser H. In vivo corneal epithelial permeability following treatment with prostaglandin analogs. J Ocul Pharmacol Ther 2007;23:445\u2013451.","journal-title":"J Ocul Pharmacol Ther"},{"key":"754_CR5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/IJG.0b013e31815a3472","volume":"17","author":"R.L. Gross","year":"2008","unstructured":"Gross RL, Peace JH, Smith SE, et al. Duration of IOP reduction with travoprost BAK-free solution. J Glaucoma 2008;17:217\u2013222.","journal-title":"J Glaucoma"},{"key":"754_CR6","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1167\/iovs.07-0266","volume":"48","author":"C. Baudouin","year":"2007","unstructured":"Baudouin C, Riancho L, Warnet JM, Brignole F. In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci 2007;48:4123\u20134128.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"754_CR7","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/ICO.0b013e31815cf651","volume":"27","author":"M.Y. Kahook","year":"2008","unstructured":"Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with SofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea 2008;27:339\u2013343.","journal-title":"Cornea"},{"key":"754_CR8","first-page":"221","volume":"21","author":"M.A. Lemp","year":"1995","unstructured":"Lemp MA. Report of the National Eye Institute\/Industry Workshop on clinical trials in dry eyes. CLAO J 1995;21:221\u2013232.","journal-title":"CLAO J"},{"key":"754_CR9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00003226-200305000-00001","volume":"22","author":"A.M. Bawazeer","year":"2003","unstructured":"Bawazeer AM, Hodge WG. One-minute Schirmer test with anesthesia. Cornea 2003;22:285\u2013287.","journal-title":"Cornea"},{"key":"754_CR10","unstructured":"Standard least squares: random effects. In: JMP statistics and graphics guide, release 7. Cary, North Carolina: SAS Institute; 2007. p. 341\u2013357."},{"key":"754_CR11","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1002\/sim.2191","volume":"24","author":"A. Yafune","year":"2005","unstructured":"Yafune A, Funatogawa T, Ishiguro M. Extended information criterion (EIC) approach for linear mixed effects models under restricted maximum likelihood (REML) estimation. Stat Med 2005;24:3417\u20133429.","journal-title":"Stat Med"},{"key":"754_CR12","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1136\/bjo.2004.064212","volume":"89","author":"J.R. Phillips","year":"2005","unstructured":"Phillips JR. Monovision slows juvenile myopia progression unilaterally. Br J Ophthalmol 2005;89:1196\u20131200.","journal-title":"Br J Ophthalmol"},{"key":"754_CR13","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/archopht.1960.01840010538009","volume":"64","author":"C. Hanna","year":"1960","unstructured":"Hanna C, O\u2019Brien JE. Cell production and migration in the epithelial layer of the cornea. Arch Ophthalmol 1960;64:536\u2013539.","journal-title":"Arch Ophthalmol"},{"key":"754_CR14","first-page":"613","volume":"2","author":"J.C. Henry","year":"2008","unstructured":"Henry JC, Peace JH, Stewart JA, Stewart WC. Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy. Clin Ophthalmol 2008;2:613\u2013621.","journal-title":"Clin Ophthalmol"},{"key":"754_CR15","first-page":"5.2","volume-title":"Clinical ophthalmology","author":"J.J. Kanski","year":"1984","unstructured":"Kanski JJ. Disorders of the cornea and sclera. In: Clinical ophthalmology. London: Butterworths; 1984. p. 5.2\u20135.31."},{"key":"754_CR16","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/IJG.0b013e31815c5f4f","volume":"17","author":"E.W. Leung","year":"2008","unstructured":"Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 2008;17:350\u2013355.","journal-title":"J Glaucoma"},{"key":"754_CR17","first-page":"73","volume":"37","author":"N.N. Daoud","year":"1983","unstructured":"Daoud NN, Dickinson NA, Gilbert P. Antimicrobial activity and physico-chemical properties of some alkyldimethylbenzylammonium chlorides. Microbios 1983;37:73\u201385.","journal-title":"Microbios"},{"key":"754_CR18","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/00061198-200312000-00007","volume":"12","author":"K. Inoue","year":"2003","unstructured":"Inoue K, Okugawa K, Kato S, et al. Ocular factors relevant to anti-glaucomatous eyedrop-related keratoepitheliopathy. J Glaucoma 2003;12:480\u2013485.","journal-title":"J Glaucoma"},{"key":"754_CR19","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1167\/iovs.04-1331","volume":"46","author":"J.M. Guenoun","year":"2005","unstructured":"Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva derived epithelial cells. Invest Ophthalmol Vis Sci 2005;46:2444\u20132450.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"754_CR20","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1167\/iovs.05-0776","volume":"46","author":"J.M. Guenoun","year":"2005","unstructured":"Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F. In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci 2005;46:4594\u20134599.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"754_CR21","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1442-9071.2006.01237.x","volume":"34","author":"N. Li","year":"2006","unstructured":"Li N, Chen XM, Zhou Y, Wei ML, Yao X. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials. Clin Exp Ophthalmol 2006;34:755\u2013764.","journal-title":"Clin Exp Ophthalmol"},{"key":"754_CR22","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1185\/030079907X178720","volume":"23","author":"P. Denis","year":"2007","unstructured":"Denis P, Lafuma A, Khoshnood B, Mimaud V, Berdeaux G. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy. Curr Med Res Opin 2007;23:601\u2013608.","journal-title":"Curr Med Res Opin"},{"key":"754_CR23","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/01.ijg.0000212274.50229.c6","volume":"16","author":"R.A. Lewis","year":"2007","unstructured":"Lewis RA, Katz GJ, Weiss MJ, et al. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma 2007;16:98\u2013103.","journal-title":"J Glaucoma"},{"key":"754_CR24","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/IJG.0b013e318050ab7a","volume":"16","author":"R.S. Kumar","year":"2007","unstructured":"Kumar RS, Istiantoro VW, Hoh ST, Ho CL, Oen FT, Aung T. Efficacy and safety of a systematic switch from latanoprost to travoprost in patients with glaucoma. J Glaucoma 2007;16:606\u2013609.","journal-title":"J Glaucoma"},{"key":"754_CR25","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/archopht.121.11.1537","volume":"121","author":"K. Miyata","year":"2003","unstructured":"Miyata K, Amano S, Sawa M, Nishida T. A novel grading method for superficial punctate keratopathy magnitude and its correlation with corneal epithelial permeability. Arch Ophthalmol 2003;121:1537\u20131539.","journal-title":"Arch Ophthalmol"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-009-0754-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10384-009-0754-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-009-0754-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T16:20:27Z","timestamp":1559146827000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10384-009-0754-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["754"],"URL":"https:\/\/doi.org\/10.1007\/s10384-009-0754-8","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}